Non Small Cell Lung Cancer Clinical Trials in Salt Lake City, Utah

20 studies are recruiting for non small cell lung cancer in Salt Lake City, Utah right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

    This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah
    Locations
    17 in total
    Run by
    Aulos Bioscience, Inc.

    See if you can join NCT05267626 on ClinicalTrials.gov

  2. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Clinical Study Site, Salt Lake City, Utah
    Locations
    285 in total
    Run by
    Summit Therapeutics

    See if you can join NCT06767514 on ClinicalTrials.gov

  3. A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

    This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab mon…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Huntsman Cancer Institute ( Site 0042), Salt Lake City, Utah
    Locations
    269 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06312137 on ClinicalTrials.gov

  4. A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

    This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical ([225Ac]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administe…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Huntsman Cancer Institute, Salt Lake City, Utah
    Locations
    14 in total
    Run by
    Aktis Oncology, Inc.

    See if you can join NCT07020117 on ClinicalTrials.gov

  5. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

    The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for rec…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Utah Cancer Specialists, Salt Lake City, Utah
    Locations
    57 in total
    Run by
    Guardant Health, Inc.

    See if you can join NCT05059444 on ClinicalTrials.gov

  6. A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

    The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Local Institution - 0302, Salt Lake City, Utah
    Locations
    326 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT06561386 on ClinicalTrials.gov

  7. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah
    Locations
    39 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06465069 on ClinicalTrials.gov

  8. Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

    A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Huntsman Cancer Institute, Salt Lake City, Utah
    Locations
    38 in total
    Run by
    TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

    See if you can join NCT06343402 on ClinicalTrials.gov

  9. First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

    Study STX-721-101/PFL-721CI101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721/PFL-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR or HER2 exon 20 insertion (ex20ins) mutati…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Utah - Huntsman Cancer Institute - PPDS, Salt Lake City, Utah
    Locations
    25 in total
    Run by
    Pierre Fabre Medicament

    See if you can join NCT06043817 on ClinicalTrials.gov

  10. Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

    The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Utah Cancer Specialists, Salt Lake City, Utah
    Locations
    153 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT06881784 on ClinicalTrials.gov

  11. MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

    The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Huntsman Cancer Institute, Salt Lake City, Utah
    Locations
    52 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06586515 on ClinicalTrials.gov

  12. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

    This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Intermountain/LDS Hospital Ph 1 Research Program, Salt Lake City, Utah
    Locations
    14 in total
    Run by
    NextCure, Inc.

    See if you can join NCT06774963 on ClinicalTrials.gov

  13. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
    Locations
    440 in total
    Run by
    Pfizer

    See if you can join NCT07222566 on ClinicalTrials.gov

  14. BBO-11818 in Adult Subjects With KRAS Mutant Cancer

    A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Huntsman Cancer Institute, Salt Lake City, Utah
    Locations
    17 in total
    Run by
    TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

    See if you can join NCT06917079 on ClinicalTrials.gov

  15. Machine Learning Approaches to Personalized Therapy for Advanced Non-small Cell Lung Cancer With Real-World Data

    This research will leverage machine learning (ML) and causal inference techniques applied to real-world data (RWD) to generate evidence that personalizes treatment strategies for patients with advanced non-small cell lung cancer (aNSCLC). Rather than influencing regulatory decisions or clinical gui…

    Stage
    Not phased
    Ages
    Any age
    Site
    Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah
    Run by
    University of Utah

    See if you can join NCT06934343 on ClinicalTrials.gov

  16. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Huntsman Cancer Institute, Salt Lake City, Utah
    Locations
    14 in total
    Run by
    Verastem, Inc.

    See if you can join NCT07020221 on ClinicalTrials.gov

  17. JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

    To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Intermountain Medical Center, Salt Lake City, Utah
    Locations
    50 in total
    Run by
    University of Texas Southwestern Medical Center

    See if you can join NCT02468024 on ClinicalTrials.gov

  18. Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

    This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tum…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah
    Locations
    15 in total
    Run by
    Tango Therapeutics, Inc.

    See if you can join NCT06810544 on ClinicalTrials.gov

  19. VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

    This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curat…

    Stage
    Phase 1
    Ages
    18 to 80
    Site
    Utah Cancer Specialists (site 203), Salt Lake City, Utah
    Locations
    15 in total
    Run by
    VM Oncology, LLC

    See if you can join NCT03556228 on ClinicalTrials.gov

  20. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Salt Lake City, Utah
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.